MDUFA Negotiations Mellow Out Over Opposing Wish Lists
This article was originally published in Clinica
Executive Summary
FDA and industry took a step back from active negotiations of new user-fee provisions at a recent meeting to examine the technical details and basic assumptions of some of the programs that have been identified for possible user-fee support when the program is reauthorized in 2017.